The Voice of Rare Disease
Patients in Europe
List of the latest marketing authorisations and orphan medicinal products designations
Detailed information on European orphan medicinal products designation applications is available on the EMAwebsite. A full list of designated and authorised orphan medicinal products in Europe available at: ec.europa.eu.
Learn more about the Orphan designation process in Europe
Recent marketing authorisations
Medicinal Product | Marketing Authorisation Holder | Therapeutic Indication | Date of Marketing Authorisation |
| Alofisel® (darvadstrocel) | Tigenix, S.A.U. | Complex anal fistulas in adults with Crohn’s disease | 23/03/2018 |
| Amglidia® (glibenclamide) | Ammtrek | Neonatal diabetes | 24/05/2018 |
| Crysvita® (burosumab) | Kyowa Kirin Limited | X-linked hypophosphataemia | 19/02/2018 |
Jorveza® (budesonide) | Dr. Falk Pharma GmbH | Eosinophilic oesophagitis | 08/01/2018 |
Lamzede® (velmanase alfa) | Chiesi Farmaceutici S.p.A. | Alpha-mannosidosis | 23/03/2018 |
Mylotarg® (gemtuzumab ozogamicin) | Pfizer Limited | Acute myeloid leukemia | 19/04/2018 |
| Premyvis® (letermovir) | Merck Sharp & Dohme Limited | Cytomegalovirus infection prevention following haematopoietic stem cell transplant | 08/01/2018 |
Rubraca® (rucaparib) | Clovis Oncology UK Limited | High-grade cancers of the ovary, fallopian tubes and peritoneum | 24/05/2018 |
.jpg)
No hay comentarios:
Publicar un comentario